GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genome & Co (XKRX:314130) » Definitions » Issuance of Debt

Genome (XKRX:314130) Issuance of Debt : ₩5,155 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genome Issuance of Debt?

Genome's Issuance of Debt for the three months ended in Dec. 2024 was ₩660 Mil.

Genome's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was ₩5,155 Mil.


Genome Issuance of Debt Historical Data

The historical data trend for Genome's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genome Issuance of Debt Chart

Genome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Debt
Get a 7-Day Free Trial - - - 32,509.24 5,830.21

Genome Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 662.31 - - 4,495.18 660.28

Genome Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,155 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genome Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Genome's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Genome Business Description

Traded in Other Exchanges
N/A
Address
Innovalley A-801, Pangyo-ro 253, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.

Genome Headlines

No Headlines